scispace - formally typeset
E

Eric P. Krenning

Researcher at Erasmus University Rotterdam

Publications -  413
Citations -  37391

Eric P. Krenning is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: Radionuclide therapy & Somatostatin. The author has an hindex of 103, co-authored 411 publications receiving 34109 citations. Previous affiliations of Eric P. Krenning include University Hospital Bonn & Novartis.

Papers
More filters
Journal ArticleDOI

Gastroenteropancreatic neuroendocrine tumours.

TL;DR: To improve outcome from GEP NETs, a better understanding of their biology is needed, with emphasis on molecular genetics and disease modeling, and more-reliable serum markers, better tumour localisation and identification of small lesions, and histological grading systems and classifications with prognostic application are needed.
Journal ArticleDOI

Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival

TL;DR: Treatment with peptide receptor radionuclide therapy with the radiolabeled somatostatin analog [(177)Lu-DOTA(0),Tyr(3)]octreotate has few adverse effects and compares favorably to the limited number of alternative treatment modalities.
Journal ArticleDOI

The role of somatostatin and its analogs in the diagnosis and treatment of tumors.

TL;DR: Experimental studies show that chronic administration of somatostatin analogs causes growth inhibition of a number of (transplantable) tumors in animals, including chondrosarcomas, pancreatic, prostatic, breast, and pituitary cancers.
Journal ArticleDOI

ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary.

TL;DR: ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, MidGut, Hind gut, and Unknown Primary